Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep

## Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep ### Overview Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a fixed-dose combination product containing sofosbuvir and velpatasvir. It is used for the treatment of chronic hepatitis C virus (HCV) infection. ### Primary Indications Treatment of chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, and 6 infection without cirrhosis or with decompensated cirrhosis. ### Adult Dosing The recommended dose is one tablet (sofosbuvir 400 mg/velpatasvir 100 mg) orally once daily. Duration of treatment depends on the HCV genotype and presence/severity of cirrhosis. * **Genotypes 1, 4, 5, 6:** 12 weeks. * **Genotype 2:** 12 weeks. * **Genotype 3:** 12 weeks. * **Patients with decompensated cirrhosis:** 12 weeks. May be used in combination with ribavirin based on local protocol. ### Pediatric Dosing Safety and efficacy in pediatric patients have not been established. ### Dose Adjustments No dose adjustments are recommended based on renal or hepatic impairment. However, caution is advised in severe hepatic impairment. ### Contraindications * Hypersensitivity to sofosbuvir, velpatasvir, or any excipient. * Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort). ### Adverse Effects Common adverse effects include headache and fatigue. Less common but serious adverse effects can occur, including bradycardia (especially when used with amiodarone) and reactivation of Hepatitis B virus (HBV). ### Key Drug Interactions * **Amiodarone:** Increased risk of severe symptomatic bradycardia. Avoid concurrent use or monitor cardiac rhythm closely. * **Strong P-gp inducers:** Decreased plasma concentrations of sofosbuvir and velpatasvir, leading to loss of efficacy. Avoid concurrent use. * **Antacids, H2-receptor antagonists, proton pump inhibitors:** May decrease velpatasvir exposure. Separate administration by at least 4 hours (for PPIs) or 12 hours (for H2RAs and antacids). ### Monitoring * HCV RNA levels to assess treatment response. * Liver function tests. * Assess for HBV reactivation in patients with evidence of prior HBV infection. * Monitor heart rate if used concurrently with amiodarone. ### Clinical Pearls * This medication can be taken with or without food. * It is crucial to complete the full course of treatment as prescribed. * Do not co-administer with other sofosbuvir-containing regimens. *** *Disclaimer: This information is intended for healthcare professionals. Please consult the most current prescribing information and relevant clinical guidelines for complete details before initiating therapy.*